Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

Company Performance - Arvinas, Inc. reported a quarterly loss of $0.97 per share, which was better than the Zacks Consensus Estimate of a loss of $1.48, and an improvement from a loss of $1.54 per share a year ago, representing an earnings surprise of 34.46% [1] - The company posted revenues of $25.3 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 18.09%, and down from $32.5 million in the same quarter last year [1] - Over the last four quarters, Arvinas has surpassed consensus EPS estimates three times but has topped consensus revenue estimates only once [1] Stock Outlook - Arvinas shares have declined approximately 21.6% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [2] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates at -$0.82 on revenues of $65.22 million for the coming quarter, and -$5.02 on revenues of $173.47 million for the current fiscal year [4] Industry Context - The Medical - Biomedical and Genetics industry, to which Arvinas belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [5] - Another company in the same industry, Liquidia Technologies, Inc., is expected to report a quarterly loss of $0.32 per share, reflecting a year-over-year change of -77.8%, with revenues projected at $4.31 million, down 4% from the previous year [5]